Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2025-12-26 @ 1:18 AM
Study NCT ID:
NCT04351334
Status:
COMPLETED
Last Update Posted:
2024-09-19
First Post:
2020-04-15
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-11-01
Completion Date Type:
ACTUAL
First Submit Date:
2020-04-15
First Submit QC Date:
None
Study First Post Date:
2020-04-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-11-01
Results First Submit QC Date:
None
Results First Post Date:
2024-09-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-16
Last Update Post Date:
2024-09-19
Last Update Post Date Type:
ACTUAL